Cerus Corporation (CERS) is a $271 million market cap company focused on blood transfusion products. The company has viable products and anticipates it's increasing sales of platelet products is removing some previous sales ramp uncertainty. By expanding its supply agreement with the French National Blood Service, EFS, and the American Red Cross (plus increased funding from BARDA), Cerus is seeing positive signs for INTERCEPT Platelet systems demand. The company markets its systems in the U.S., Europe, and Middle East. With a global market of over $12 billion per year, the platelet replacement market is certainly substantial. The blood preparation market is expected to reach a whopping $64 billion by 2024. The company is also collaborating with Central California Blood Center to manufacture pathogen-reduced cryoprecipitate as a novel biologic, and is advancing its INTERCEPT red cell commercial development program including a planned FDA submission.
The company is overcoming obstacles faced by many players in the platelet manufacturing market space, including various shortages in production components and challenges in its commercial rollout. In contrast to the majority of blood components, which can be frozen, blood platelets are required to be stored at ambient temperature to be active and work properly. Unfortunately, these temperatures and conditions are ideal for the growth of bacteria. Incidence of bacterial contamination is believed to be significant, and is higher than the risk of viral contamination, which are also serious. Experts report infection can be the cause of medical complications and mortality, much of which may go unreported because of the presence of the patient��s underlying illness. Increasing geriatric population and rising prevalence of chronic diseases such as diabetes and glomerulonephritis will increase these markets (with a CAGR of 4.4%), as well as the severity risk for safe transfusion. Safety in blood transfusion is a primary concern for CERS, as they try to meet several unmet or under-met needs in this market space. The nucleic acid targeting mechanism of action of Cerus' INTERCEPT treatment inactivates pathogens (as reported at ISBT 2017) such as Hepatitis B and C, HIV, West Nile Virus and bacteria, as well as emerging hazards such as chikungunya, malaria and dengue.
best stock buys: Star Bulk Carriers Corp.(SBLK)
Advisors' Opinion:- [By Rich Smith]
Now those new buy recommendations are rolling in. This morning, Stifel Nicolaus -- one of the best-rated analysts we have on Motley Fool CAPS -- announced a pair of such upgrades, urging investors to buy stock in Scorpio Bulkers (NYSE:SALT) and Star Bulk Carriers (NASDAQ:SBLK). Here's what you need to know.
best stock buys: CoreSite Realty Corporation(COR)
Advisors' Opinion:- [By ]
CoreSite Realty (COR) : "The data centers have been hot, but the REITS have not. I'm a buyer of this stock, not a seller."
Hi-Crush Partners (HCLP) : "This sector has gotten way too hot."
- [By Jack Delaney]
Take CoreSite Realty Corp. (NYSE: COR), for example. The stock price not only climbed 43.66% from 2017 to 2018, but it also pays its shareholders a dividend of $3.92 per share.
- [By ]
In the Lightning Round, Cramer was bullish on Align Technology (ALGN) , Berkshire Hathaway (BRK.A) (BRK.B) , Criticare Systems Inc. (CMD) , Thermo Fisher Scientific (TMO) , IAC Interactive (IAC) and CoreSite Realty (COR) .
best stock buys: Caseys General Stores, Inc.(CASY)
Advisors' Opinion:- [By Shane Hupp]
Wall Street analysts forecast that Casey’s General Stores (NASDAQ:CASY) will announce sales of $2.14 billion for the current quarter, Zacks reports. Five analysts have issued estimates for Casey’s General Stores’ earnings. The highest sales estimate is $2.18 billion and the lowest is $2.12 billion. Casey’s General Stores reported sales of $1.85 billion in the same quarter last year, which would suggest a positive year over year growth rate of 15.7%. The business is scheduled to announce its next quarterly earnings report on Monday, June 4th.
best stock buys: Pointer Telocation Ltd.(PNTR)
Advisors' Opinion:- [By Lisa Levin]
Pointer Telocation Ltd. (NASDAQ: PNTR) is projected to report quarterly earnings at $0.22 per share on revenue of $20.22 million.
Tecogen Inc. (NASDAQ: TGEN) is estimated to report quarterly earnings at $0.01 per share on revenue of $9.43 million.
best stock buys: ANI Pharmaceuticals, Inc.(ANIP)
Advisors' Opinion:- [By Joseph Griffin]
Canaccord Genuity set a $82.00 target price on ANI Pharmaceuticals (NASDAQ:ANIP) in a research report released on Tuesday morning. The firm currently has a buy rating on the specialty pharmaceutical company’s stock.
best stock buys: Northern Oil and Gas, Inc.(NOG)
Advisors' Opinion:- [By Ethan Ryder]
Northern Oil and Gas Inc. (NYSEAMERICAN:NOG) has received a consensus recommendation of “Hold” from the eight research firms that are presently covering the firm, MarketBeat.com reports. Seven investment analysts have rated the stock with a hold rating and one has issued a buy rating on the company. The average 12 month price target among brokers that have covered the stock in the last year is $2.20.
- [By Matthew DiLallo]
Shares of Northern Oil & Gas, Inc. (NYSEMKT:NOG) are flying high, up 12% as of 10:30 a.m. EDT, after the company reported better-than-expected first-quarter results.
- [By Ezra Schwarzbaum]
SunTrust analyst Neal Dingmann upgraded shares of Northern Oil & Gas, Inc. (NYSE: NOG) from Hold to Buy and increased his price target from $2 to $4.
No comments:
Post a Comment